29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma

Background

Arising from the arachnoid villi cells, meningioma constitutes 35% of all the primary brain tumors. According to WHO, meningiomas can be classified into 3 grades i.e. WHO grade I (typical), WHO grade II (atypical), WHO grade III (anaplastic), further dividing them into 15 subtypes. Based solely on histology, nine of these subtypes comes under WHO grade I and three each in grade II and grade III. Though benign, 80% meningiomas can be treated by resection and chemotherapy thereafter. However, 20% recur and need further surgery, radiotherapy or another round of chemotherapy. Moreover, comorbidities like neurological and cognitive disorders can be caused by relatively indolent meningiomas. Impede cognition, in grade I patients further diminishes the life surviving conditions. Though, meningiomas are the most common intracranial tumors, occurrence of multiple meningioma (10% of the affected population) present another set of complications to deal with. Biomarkers as ‘targets’ may provide a better treatment and prognostic factors for these patients and their follow up routines.

Methods

Proteome studies that aim to decipher novel insights in the tumors provide a vast reservoir for likely molecular targets. However, non-availability of in depth proteomic re-searches in this field renders the treatment dubious. Herein, we present a proteome analysis of meningioma patients aimed to decipher the role of selected functional proteins which may serve to be target for therapies.

Results

The study presented here dwell on the proteins like adenylate kinase 2 (AK2), collagen type 1 alpha 1 (COL1A1)), plasminogen (PLG), found via mass spectrometry analysis. Simultaneously, cell sorting by FACS was used to support the mass spec findings.

Conclusions

Furthermore, these ‘protein markers’ might be targeted to identify another panel of proteins that can be screened in a large patient cohort using targeted proteomics.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sir Ganga Ram Hospital.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.